Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Efficacy and Safety of Telmisartan Compared With Losartan
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 98
- Registration Number
- NCT06431477
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Telmisartan in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Tyler J Curiel
- Target Recruit Count
- 36
- Registration Number
- NCT06168487
- Locations
- 🇺🇸
Dartmouth Health, Lebanon, New Hampshire, United States
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 116
- Registration Number
- NCT05843162
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 107
- Registration Number
- NCT04736329
- Locations
- 🇪🇬
Kasralainy hospital, faculty of medicine, Cairo university, Cairo, Egypt
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Telmisartan in Respiratory Failure Due to COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Abraham Edgar Gracia-Ramos
- Target Recruit Count
- 66
- Registration Number
- NCT04510662
- Locations
- 🇲🇽
Hospital Regional de Alta Especialidad de Zumpango, Zumpango, Estado De Mexico, Mexico
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 16
- Registration Number
- NCT04359953
- Locations
- 🇫🇷
CHU de Strasbourg, Strasbourg, France
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 412
- Registration Number
- NCT04356495
- Locations
- 🇫🇷
Bordeaux university Hospital, Bordeaux, France
🇫🇷CNGE, Paris, France
🇫🇷CHU de Montpellier, Montpellier, France
Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 63744
- Registration Number
- NCT04354350
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40048
- Registration Number
- NCT04354376
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.